T32 Cincinnati Pediatric Clinical Pharmacology Training Program

T32 辛辛那提儿科临床药理学培训计划

基本信息

  • 批准号:
    10631893
  • 负责人:
  • 金额:
    $ 16.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-05-16 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY This is a competitive renewal application for the continuation of a highly collaborative and successful pediatric clinical pharmacology training program at Cincinnati Children's Hospital Medical Center and the University of Cincinnati. The program will train a new generation of pediatric investigators to assume leadership roles in the application of innovative, high impact quantitative clinical pharmacology approaches to improve the development, rational use and tailoring of new and existing drug therapies for neonates, infants, children, adolescents and young adults. The need for pediatric clinical pharmacology research and training has never been greater. The T32 Training Program in Pediatric Clinical Pharmacology at Cincinnati Children's Hospital Medical Center (CCHMC) is designed specifically to address this critical need. The program is based in the Division of Clinical Pharmacology, which is jointly a unit within the Department of Pediatrics and the University of Cincinnati, College of Medicine (UCCoM). The program outlined in this renewal application draws on strong leadership and a diverse group of well-established faculty mentors actively involved in subspecialty clinical pharmacology research, representing 18 divisions within the Department of Pediatrics, the Departments of Pharmacology & Systems Physiology and Biomedical Informatics at the UCCoM, and the James L. Winkle College of Pharmacy. The program has tremendous institutional support and takes advantage of broad areas of distinction and resources within a uniquely collaborative environment. The T32 training program is innovative and well aligned with the objectives outlined in the program announcement as it: (1) has a focus in early and later phase studies in multiple and diverse pediatric populations through ongoing research collaborations with all major pediatric subspecialties; (2) involves the application and development of innovative quantitative methodologies such as PK/PD modeling and pharmacometrics, quantitative systems pharmacology modeling and simulation and model-informed clinical trial design; (3) is embedded in the institutional and UCCoM pharmacogenetic/genomics research and training endeavors through the Center for Pediatric Genomics; (4) is closely integrated with Bioinformatics and Health Services and Outcomes Research; and (5) can rely on over 10 years of a well-established curriculum after two funding cycles as a successful training program. The program provides a unique training experience to MDs, PharmDs, and PhDs to become the next generation of leaders whose work will advance pediatric clinical pharmacology and to have an extraordinary impact on pediatric therapeutics and health outcomes for children. The program has successfully opened new avenues to enlarge the pool of talented young clinical investigators with a career interest in pediatric therapeutics.
项目总结 这是一项具有竞争力的续订申请,旨在延续高度协作和成功的儿科 辛辛那提儿童医院医学中心和加州大学的临床药理学培训计划 辛辛那提。该计划将培训新一代儿科调查人员,以在 应用创新的、高影响的定量临床药理学方法来改善 为新生儿、婴儿、儿童开发、合理使用和定制新的和现有的药物疗法, 青少年和青壮年。儿科临床药理学研究和培训的需求 变得更伟大。辛辛那提儿童医院儿科临床药理学T32培训项目 医疗中心(CCHMC)是专门为满足这一关键需求而设计的。该程序基于 临床药理科,这是儿科和大学内的一个联合单位 辛辛那提医学院(UCCoM)。此续订申请中概述的计划借鉴了强大的 领导力和一批积极参与专科临床的资深教师导师 药理学研究,代表儿科系内的18个司, UCCoM的药理学和系统生理学与生物医学信息学,以及James L.Winkle 药学院。该计划得到了巨大的制度支持,并利用了广泛的领域 在一个独特的协作环境中拥有独特的优势和资源。T32培训计划是 创新并与计划公告中概述的目标很好地结合在一起,因为它:(1)重点放在 通过正在进行的研究在多个不同的儿科人群中进行早期和后期研究 与所有主要儿科分科合作;(2)涉及应用和发展 创新的定量方法,如PK/PD建模和药物计量学,定量系统 药理学建模和仿真以及模型知晓的临床试验设计;(3)嵌入 机构和UCCoM药物遗传学/基因组学研究和培训努力通过 儿科基因组学;(4)与生物信息学、卫生服务和结果研究紧密结合; 和(5)在两个资助周期后,可以依靠超过10年的成熟课程作为成功的 培训计划。该计划为未来成为医学博士、药学博士和博士提供独特的培训体验 下一代领导人的工作将推动儿科临床药理学,并拥有 对儿童的儿科治疗和健康结果的特殊影响。该计划已成功 开辟了新的途径,以扩大具有职业兴趣的有才华的年轻临床研究人员的人才库 儿科治疗学。

项目成果

期刊论文数量(39)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy.
  • DOI:
    10.1002/jcph.1315
  • 发表时间:
    2019-03
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    Euteneuer JC;Kamatkar S;Fukuda T;Vinks AA;Akinbi HT
  • 通讯作者:
    Akinbi HT
Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia.
HdxSim 的基本原理、开发和验证,这是一种临床决策支持工具,用于为患有镰状细胞性贫血的儿童提供基于模型的羟基脲精确剂量。
  • DOI:
    10.1002/cpt.3119
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    6.7
  • 作者:
    Power-Hays,Alexandra;Dong,Min;Punt,Nieko;Mizuno,Tomoyuki;Smart,LukeR;Vinks,AlexanderA;Ware,RussellE
  • 通讯作者:
    Ware,RussellE
Validation of a pediatric population pharmacokinetic model for vancomycin.
  • DOI:
    10.1097/ftd.0000000000000153
  • 发表时间:
    2015-06
  • 期刊:
  • 影响因子:
    2.5
  • 作者:
    Hahn A;Frenck RW Jr;Zou Y;Vinks AA
  • 通讯作者:
    Vinks AA
Federal legislation and the advancement of neonatal drug studies.
联邦立法和新生儿药物研究的进步。
  • DOI:
    10.1016/j.jpeds.2012.08.034
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Wiles,JasonR;Vinks,AlexanderA;Akinbi,Henry
  • 通讯作者:
    Akinbi,Henry
Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TRACY A GLAUSER其他文献

TRACY A GLAUSER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TRACY A GLAUSER', 18)}}的其他基金

Clinical Pharmacology K12 Training Program
临床药理学K12培训项目
  • 批准号:
    10749592
  • 财政年份:
    2023
  • 资助金额:
    $ 16.11万
  • 项目类别:
Cincinnati Neuroscience Clinical Trials Research Center (CinciNEXT)
辛辛那提神经科学临床试验研究中心 (CinciNEXT)
  • 批准号:
    10166966
  • 财政年份:
    2018
  • 资助金额:
    $ 16.11万
  • 项目类别:
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites)
神经科学临床试验卓越网络的临床研究网站(NeuroNEXT 网站)
  • 批准号:
    10744306
  • 财政年份:
    2018
  • 资助金额:
    $ 16.11万
  • 项目类别:
Cincinnati Neuroscience Clinical Trials Research Center (CinciNEXT)
辛辛那提神经科学临床试验研究中心 (CinciNEXT)
  • 批准号:
    10593621
  • 财政年份:
    2018
  • 资助金额:
    $ 16.11万
  • 项目类别:
Cincinnati Neuroscience Clinical Trials Research Center (CinciNEXT)
辛辛那提神经科学临床试验研究中心 (CinciNEXT)
  • 批准号:
    8869050
  • 财政年份:
    2011
  • 资助金额:
    $ 16.11万
  • 项目类别:
Cincinnati Neuroscience Clinical Trials Research Center (CinciNEXT)
辛辛那提神经科学临床试验研究中心 (CinciNEXT)
  • 批准号:
    9293406
  • 财政年份:
    2011
  • 资助金额:
    $ 16.11万
  • 项目类别:
Cincinnati Neuroscience Clinical Trials Research Center (CinciNEXT)
辛辛那提神经科学临床试验研究中心 (CinciNEXT)
  • 批准号:
    8721489
  • 财政年份:
    2011
  • 资助金额:
    $ 16.11万
  • 项目类别:
Cincinnati Neuroscience Clinical Trials Research Center (CinciNEXT)
辛辛那提神经科学临床试验研究中心 (CinciNEXT)
  • 批准号:
    8337819
  • 财政年份:
    2011
  • 资助金额:
    $ 16.11万
  • 项目类别:
Cincinnati Neuroscience Clinical Trials Research Center (CinciNEXT)
辛辛那提神经科学临床试验研究中心 (CinciNEXT)
  • 批准号:
    8532063
  • 财政年份:
    2011
  • 资助金额:
    $ 16.11万
  • 项目类别:
Cincinnati Neuroscience Clinical Trials Research Center (CinciNEXT)
辛辛那提神经科学临床试验研究中心 (CinciNEXT)
  • 批准号:
    8241271
  • 财政年份:
    2011
  • 资助金额:
    $ 16.11万
  • 项目类别:

相似海外基金

National Career Development Program for Researchers in Pediatric Clinical Pharmacology
儿科临床药理学研究人员国家职业发展计划
  • 批准号:
    11001312
  • 财政年份:
    2024
  • 资助金额:
    $ 16.11万
  • 项目类别:
Clinical Pharmacology Quality Assurance (CPQA)
临床药理学质量保证(CPQA)
  • 批准号:
    10850504
  • 财政年份:
    2023
  • 资助金额:
    $ 16.11万
  • 项目类别:
Understanding the clinical pharmacology of marijuana-tobacco co-administration
了解大麻-烟草联合用药的临床药理学
  • 批准号:
    10660409
  • 财政年份:
    2023
  • 资助金额:
    $ 16.11万
  • 项目类别:
Clinical Pharmacology K12 Training Program
临床药理学K12培训项目
  • 批准号:
    10749592
  • 财政年份:
    2023
  • 资助金额:
    $ 16.11万
  • 项目类别:
Clinical Pharmacology of Nicotine Enantiomers
尼古丁对映体的临床药理学
  • 批准号:
    10570635
  • 财政年份:
    2023
  • 资助金额:
    $ 16.11万
  • 项目类别:
Clinical Pharmacology Quality Assurance (CPQA)
临床药理学质量保证(CPQA)
  • 批准号:
    10650277
  • 财政年份:
    2022
  • 资助金额:
    $ 16.11万
  • 项目类别:
AstraZeneca Secondment for Clinical Pharmacology Training
阿斯利康借调临床药理学培训
  • 批准号:
    MR/W003538/1
  • 财政年份:
    2021
  • 资助金额:
    $ 16.11万
  • 项目类别:
    Research Grant
Clinical Pharmacology Approaches towards Accelerating HIV Cure Initiatives
加速艾滋病毒治疗计划的临床药理学方法
  • 批准号:
    10475670
  • 财政年份:
    2021
  • 资助金额:
    $ 16.11万
  • 项目类别:
Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program
杜克大学-北卡罗来纳大学合作儿科临床药理学博士后培训项目
  • 批准号:
    10400677
  • 财政年份:
    2021
  • 资助金额:
    $ 16.11万
  • 项目类别:
Clinical Pharmacology Approaches towards Accelerating HIV Cure Initiatives
加速艾滋病毒治疗计划的临床药理学方法
  • 批准号:
    10258039
  • 财政年份:
    2021
  • 资助金额:
    $ 16.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了